Skip to main content

Tandem bispecific broadly neutralizing antibody - a novel approach to HIV-1 treatment

The last decade has led to a significant advance in our knowledge of HIV-1 latency and immunity. However, we are still not close to finding a cure for HIV-1. Although combination antiretroviral therapy (cART) has led to increased survival, almost close to that of the general population, it is still not curative. In the current issue of the JCI, Wu et al. studied the prophylactic and therapeutic potential of an engineered tandem bispecific broadly neutralizing antibody (bs-bnAb), BiIA-SG. This bnAb's breadth and potency were highly effective in protection and treatment settings, as measured by complete viremia control following direct infusion, as well as elimination of infected cells and delay in viral rebound when delivered with a recombinant vector. These observations underscore the need for the clinical development of BiIA-SG for the prevention of HIV-1.

Citation: 

Ferrari, G. "Tandem bispecific broadly neutralizing antibody - a novel approach to HIV-1 treatment." Journal of Clinical Investigation 128, no. 6 (June 1, 2018): 2189-2191. (Review)

Published Date: 
Friday, June 1, 2018
Published In: 
The Journal of Clinical Investigation